- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 890655-80-8] Verdiperstat
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-17646 |
| Brand: | MCE |
| CAS: | 890655-80-8 |
Overview
| MDL | MFCD30533444 |
|---|---|
| Molecular Weight | 253.32 |
| Molecular Formula | C11H15N3O2S |
| SMILES | O=C(N1)C(NC=C2)=C2N(CCOC(C)C)C1=S |
1 Publications Citing Use of MCE
Summary
Verdiperstat (AZD3241) is a selective, irreversible and orally active myeloperoxidase (MPO) inhibitor, with an IC 50 of 630 nM, and can be used in the research of neurodegenerative brain disorders.
IC50 & Target
IC50: 630 nM (Myeloperoxidase) [1]
In Vitro
Verdiperstat (AZD3241) is a myeloperoxidase (MPO) inhibitor, with an IC 50 of 630 nM, and is used in the research of neurodegenerative brain disorders [1] . Verdiperstat (AZD3241) selectively and irreversibly inhibits myeloperoxidase, and may involves reduction of oxidative stress leading to reduction of sustained neuroinflammation [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02388295 | AstraZeneca |
Multiple System Atrophy, MSA
|
April 27, 2015 | Phase 2 |
| NCT05184569 | Peter Ljubenkov, MD|National Institutes of Health (NIH)|Alzheimer´s Association|National Institute on Aging (NIA)|University of California, San Francisco |
Semantic Dementia
|
April 14, 2022 | Phase 1 |
| NCT00729443 | AstraZeneca |
Healthy Volunteers
|
July 2008 | Phase 1 |
| NCT03952806 | Biohaven Pharmaceuticals, Inc. |
Multiple System Atrophy
|
July 29, 2019 | Phase 3 |
| NCT05086094 | Biohaven Pharmaceuticals, Inc. |
Multiple System Atrophy (MSA)
|
||
| NCT04297683 | Merit E. Cudkowicz, MD|Massachusetts General Hospital |
Amyotrophic Lateral Sclerosis
|
July 14, 2020 | Phase 2|Phase 3 |
| NCT01527695 | AstraZeneca |
Parkinson´s Disease
|
April 2012 | Phase 2 |
| NCT04436510 | Merit E. Cudkowicz, MD|Biohaven Pharmaceuticals, Inc.|Massachusetts General Hospital |
Amyotrophic Lateral Sclerosis
|
July 28, 2020 | Phase 2|Phase 3 |
| NCT04616456 | Brigham and Women´s Hospital|Biohaven Pharmaceuticals, Inc. |
Multiple System Atrophy|Multiple System Atrophy, Cerebellar Variant|Multiple System Atrophy, Parkinson Variant (Disorder)|Multiple System Atrophy (MSA) With Orthostatic Hypotension
|
December 30, 2020 | Early Phase 1 |
| NCT00914303 | AstraZeneca |
Healthy
|
June 2009 | Phase 1 |
| NCT01603069 | AstraZeneca |
Parkinson´s Disease
|
October 2012 | Phase 2 |
| NCT01457807 | AstraZeneca |
Parkinson´s Disease
|
November 2011 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 150 mg/mL ( 592.14 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.9476 mL | 19.7379 mL | 39.4758 mL |
| 5 mM | 0.7895 mL | 3.9476 mL | 7.8952 mL |
| 10 mM | 0.3948 mL | 1.9738 mL | 3.9476 mL |
References
- [1] Johnström P, et al. Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. Nucl Med Biol. 2015 Jun;42(6):555-60.
- [2] Jucaite A, et al. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.